NCT02888080View on ClinicalTrials.gov

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 19, 2016

Primary Completion Date

March 4, 2019

Study Completion Date

March 4, 2019

Conditions
Pulmonary Sarcoidosis
Interventions
DRUG

ACZ885

ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.

DRUG

Placebo

Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.

Trial Locations (8)

12208

Novartis Investigative Site, Albany

30625

Novartis Investigative Site, Hanover

44195

Novartis Investigative Site, Cleveland

45147

Novartis Investigative Site, Essen

60596

Novartis Investigative Site, Frankfurt

35294-0006

Novartis Investigative Site, Birmingham

3435 CM

Novartis Investigative Site, Nieuwegein

3015 CE

Novartis Investigative Site, Rotterdam

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY